All AbMole products are for research use only, cannot be used for human consumption.
Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis. Necrosulfonamide significantly decreases BV6/DAC-induced cell death in MV4-11 cells. Necrosulfonamide is also an effective inhibitor of the necroptotic pathway induced by STS in the presence of caspase inhibitor.
JACC-BASIC TRANSL SC. 2023 May 31.
PCSK9 Promotes Hypoxia-Induced Endothelial Cell Pyroptosis by Regulating Smac Mitochondrion-Cytoplasm Translocation in Critical Limb Ischemia
Necrosulfonamide purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | HaCaT cells |
| Preparation method | For therapy, necrosulfonamide (NSA) was applied in different concentrations (1, 5 and 10 μM) 1 h after SM exposure. The medium was not removed during the experiment procedure. DMSO served as solvent and was added to the THP-medium for the sham-treated wells in equivalent amounts. After NSA therapy, cells were incubated for another 24 h under before mentioned conditions. |
| Concentrations | 1, 5 and 10 μM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | C57BL/6J mice |
| Formulation | DMSO |
| Dosages | 20 mg/kg |
| Administration | Intraperitoneal injection |
| Molecular Weight | 461.47 |
| Formula | C18H15N5O6S2 |
| CAS Number | 1360614-48-7 |
| Solubility (25°C) | DMSO ≥ 25 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Bae JH, et al. Arch Pharm Res. Chemical regulation of signaling pathways to programmed necrosis.
| Related Necroptosis Products |
|---|
| GW806742X
GW806742X is an ATP site-targeing kinase inhibitor (IC50 in nM = 2/VEGFR2, 15/SRC, 47/C-FMS, 851/GSK3, 9016/ERBB2, 9120/FGFR) with potent antiproliferation activity against cancer cultures (IC50 in nM = 5/HUVEC-v, 424/HUVEC-b, 81/HEF, 453/MDA468, 470/A375P, 693/HT29, 734/PC3), GW806742X is now better known as Compound 1 for its anti-necroptosis activity via affinity interaction with ML |
| GSK2982772
GSK2982772 is a potent, selective receptor interacting protein kinase 1 (RIPK1) inhibitor with IC50 values of 16 nM and 20 nM against human and monkey RIP1, respectively. |
| GSK547
GSK547 is a potent and highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) and also inhibits necroptosis. |
| PK68
PK68 is a potent and selective type II RIPK1 inhibitor with an IC50 value of approximately 90 nM that inhibits RIPK1-dependent necroptosis. It can be used in studies related to inflammatory diseases and cancer metastasis. |
| GSK-843
GSK-843 is a potent receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
